PT - JOURNAL ARTICLE AU - Sukali, Gloria AU - Busang, Jacob AU - Dreyer, Jaco AU - Khoza, Thandeka AU - Delphin, Marion AU - Okesola, Nonhlanhla AU - Herbst, Carina AU - Waddilove, Elizabeth AU - Upton, Janine AU - Seeley, Janet AU - Iwuji, Collins AU - Anderson, Motswedi AU - Matthews, Philippa C AU - Shahmanesh, Maryam TI - HIV PrEP programmes as a framework for diagnosing and treating HBV infection in adolescents and young adults in KwaZulu-Natal, South Africa AID - 10.1101/2024.11.29.24318178 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.29.24318178 4099 - http://medrxiv.org/content/early/2024/12/05/2024.11.29.24318178.short 4100 - http://medrxiv.org/content/early/2024/12/05/2024.11.29.24318178.full AB - Background Hepatitis B virus (HBV) is a neglected public health threat with poor community awareness and access to prevention, despite having a safe and effective vaccine. There are still gaps in diagnosis and treatment, particularly in the World Health Organization (WHO) African region. New WHO HBV guidelines, for the first time, include the use of dual therapy for HBV treatment (Tenofovir (TDF) and Emtricitabine or Lamivudine (XTC) due to challenges in accessing TDF monotherapy. TDF/XTC is also recommended as Pre-Exposure Prophylaxis (PrEP) in adolescents and adults at risk of Human Immunodeficiency Virus (HIV).HBV Screening, treatment and prevention need to be decentralized to improve access. We hypothesize that HBV programmes in African settings can use pre-existing HIV infrastructure, in particular building on PrEP programmes, for access to TDF.Methods At the Africa Health Research Institute (AHRI) in KwaZulu Natal, South Africa, the new Evaluation of Vukuzazi LiVEr disease - Hepatitis B (‘EVOLVE-HBV’, UCL ethics ref. 23221/001) research programme explored the PrEP uptake and retention cascade amongst adolescents and youth aged 15-30 year-olds living with HBV through decentralized sexual health /HIV services of the ‘Thetha nami ngithethe nawe’ and the Long-acting HIV Pre-Exposure Prophylaxis (LAPIS) study (UKZN BREC ethics ref. 473/2019 and 3735/2021). Following point of care testing (POCT) for HBsAg, follow-up venous samples were taken for laboratory confirmation.Results Over the time reviewed (May 2021 - Sept 2024), 15,847 adolescents and young adults received a ‘needs assessment’ by peer navigators in the community, of whom 3481 (21.9%) were eligible for HIV prevention interventions and referred for clinical review. 3431 (98.6%) accepted HBV POCT as part of routine screening, of whom 21 (0.6%) tested positive for HBsAg. These 21 individuals had not previously been aware of their HBV status, but one was already on antiretroviral (ART) for HIV infection. Amongst the remaining 20, 16 were considered eligible for PrEP, 1/16 (6.3%) decided not to take it and 15 (93.8%) started PrEP as a combined intervention for HBV treatment and HIV prophylaxis. When investigating follow up and retention in care, out of the 14/15 (93.3%) that were due for a refill, 8/14 (57,1%) returned for at least 1 refill, amongst whom 6/12 (50%) had two or more refills (Suppl figure 1).Conclusion Sexual health and PrEP programmes provide an important opportunity for HBV testing and treatment for young adults across high HIV burden settings. However, attrition from the care cascade at each step highlights the pressing need for interventions that address barriers to sustainable delivery of long-term care. Our HBV and PrEP programmes continue working to support education, clinical evaluation and service development for HBV in these populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGloria Sukali is funded by AHRI-UCL PhD fellowship. Philippa Matthews lab Crick core funding: CC2223Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) (ref. 473/2019) in South Africa gave ethical approval for this work. Ethics committee of University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) (ref. 3735/2021) in South Africa gave ethical approval for this work. Ethics committee of University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) (ref. 00004495/2022) in South Africa gave ethical approval for this work. Ethics committee University College London (UCL) in the United Kingdom (ref. 23221/001 EVOLVE-HBV) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.